Foley & Lardner LLP partner Louis Lehot is quoted in Law360, where he offers insight on the outlook for initial public offerings of technology companies in 2024.
Lehot said he does not expect a surge in technology IPOs this spring, given industry concerns about valuation. He noted that companies could be forced to weigh pricing concessions given investors’ current sober mood.
Lehot noted however that if interest rates do drop, thereby encouraging investors to take on more risk, and one or two technology startups go public and trade well, then IPO prospects could emerge in the year’s second half.
“You have to have one successful IPO that outperforms because it got priced at a discount,” he continued.
(Subscription required)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”